高飞;张姝玥;王致萍;夏宁邵;

• 1:厦门大学生命科学学院国家传染病诊断试剂与疫苗工程技术研究中心
• 2:厦门大学公共卫生学院分子疫苗学和分子诊断学国家重点实验室

摘要(Abstract)：

人乳头瘤病毒（human papillomavirus,HPV）是目前通过性传播最广泛的病毒之一。人类感染HPV轻则可自愈，重则会导致宫颈癌等疾病，严重危害人类健康，而疫苗是预防宫颈癌最有效的武器。本文对HPV的病毒学特征及HPV疫苗的研究现状，包括HPV分子生物学和流行病学研究、国内外已上市和临床阶段疫苗的研究进展作一综述，并进一步探讨新型疫苗的研发策略及新型佐剂的应用潜力，为未来研发更广谱、更高效的HPV疫苗提供参考。

关键词(KeyWords)： 人乳头瘤病毒;宫颈癌;流行病学;疫苗

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金（U1705283）

作者(Authors): 高飞;张姝玥;王致萍;夏宁邵;

DOI: 10.13200/j.cnki.cjb.003667

参考文献(References)：

• [1]REVAT HIDEVI S,MURUGAN A K,NAKAOKA H,et al.APOBEC:A molecular driver in cervical cancer pathogenesis[J].Cancer Lett,2021,496(1):104-116.
• [2]COURSEY T L,MCBRIDE A A.Hitchhiking of viral genomes on cellular chromosomes[J].Annual Rev Virol,2019,6(1):275-296.
• [3]BIRYUKOV J,MYERS J C,MCLAUGHLIN-DRUBIN M E,et al.Mutations in HPV18 E1^E4 impact virus capsid assembly,infectivity competence,and maturation[J].Viruses,2017,9(12):385.
• [4]GUTIERREZ-XICOTENCATL L,PEDROZA-SAAVEDRA A,CHIHU-AMPARAN L,et al.Cellular functions of HPV16 E5oncoprotein during oncogenic transformation[J].Mol Cancer Res,2021,19(2):167-179.
• [5]SCOTT M L,WOODBY B L,ULICNY J,et al.Human papillomavirus 16 E5 inhibits interferon signaling and supports episomal viral maintenance[J].J Virol,2020,94(2):e01582-19.doi:ARTN e01582-1910.1128/JVI.01582-19.
• [6]CELEGATO M,MESSA L,BERTAGNIN C,et al.Targeted disruption of E6/p53 binding exerts broad activity and synergism with paclitaxel and topotecan against HPV-transformed cancer cells[J].Cancers(Basel),2021,14(1):192.
• [7]MALLA R,KAMAL M A.E6 and E7 oncoproteins:Potential targets of cervical cancer[J].Curr Med Chem,2021,28(39):8163-8181.
• [8]LI S,HONG X,WEI Z,et al.Ubiquitination of the HPV oncoprotein E6 is critical for E6/E6AP-mediated p53 degradation[J].Front Microbiol,2019,10:2483.
• [9]ZHAO W,LIU Y,ZHANG L,et al.Micro RNA-154-5p regulates the HPV16 E7-p Rb pathway in cervical carcinogenesis by targeting CUL2[J].J Cancer,2020,11(18):5379-5389.
• [10]DOORBAR J.Molecular biology of human papillomavirus infection and cervical cancer[J].Clin Sci(Lond),2006,110(5):525-541.
• [11]ZAVALOV O,IRIZARRY R,FLAMM M,et al.Mesoscale model of the assembly and cross-linking of HPV virus-like particles[J].Virology,2019,537:53-64.
• [12]YU L L,MAJERCIAK V,ZHENG Z M.HPV16 and HPV18genome structure,expression,and post-transcriptional regulation[J].Int J Mol Sci,2022,23(9):4943.
• [13]MOHSEN M O,ZHA L,CABRAL-MIRANDA G,et al.Major findings and recent advances in virus-like particle(VLP)-based vaccines[J].Semin Immunol,2017,34:123-132.
• [14]XIE J,HEIM E N,CRITE M,et al.TBC1D5-catalyzed cycling of Ra b7 is required for retromer-mediated human papillomavirus trafficking during virus entry[J].Cell Rep,2020,31(10):107750.
• [15]HIRAO N,IWATA T,TANAKA K,et al.Transcription factor homeobox D9 is involved in the malignant phenotype of cervical cancer through direct binding to the human papillomavirus oncogene promoter[J].Gynecol Oncol,2019,155(2):340-348.
• [16]MCBRIDE A A.Human papillomaviruses:diversity,infection and host interactions[J].Nature Rev Microbiol,2022,20(2):95-108.
• [17]MUHR L S A,EKLUND C,DILLNER J.Towards quality and order in human papillomavirus research[J].Virology,2018,519:74-76.
• [18]SCHIFFMAN M,CLIFFORD G,BUONAGURO F M.Classification of weakly carcinogenic human papillomavirus types:addressing the limits of epidemiology at the borderline[J].Infect Agents Cancer,2009,4:8.
• [19]MUNOZ N,BOSCH F X,DE SANJOSE S,et al.Epidemiologic classification of human papillomavirus types associated with cervical cancer[J].N Engl J Med,2003,348(6):518-527.
• [20]WHO.Human papillomavirus and related diseases report.2021(2021-10-22)[2022-06-06].https：//hpvcentre.net/statistics/reports/X-WX.pdf.
• [21]BRUNO M T,CASSARO N,BICA F,et al.Progression of CIN1/LSIL HPV persistent of the cervix:Actual progression or CIN3 coexistence[J].Infect Dis Obstet Gynecol,2021,2021:6627531.
• [22]WU X,WANG S,LI M,et al.Conditional reprogramming:next generation cell culture[J].Acta Pharm Sin B,2020,10(8):1360-1381.
• [23]MYERS D J,KWAN E,FILLMAN E P.Epidermodysplasia verruciformis[M].Stat Pearls:Treasure Island(FL),2022.
• [24]SCHULTE-FROHLINDE R,GEORGES D,CLIFFORD G M,et al.Predicting cohort-specific cervical cancer incidence from population-based surveys of human papilloma virus prevalence:A worldwide study[J].Am J Epidemiol,2022,191(3):402-412.
• [25]SOHEILI M,KEYVANI H,SOHEILI M,et al.Human papilloma virus:A review study of epidemiology,carcinogenesis,diagnostic methods,and treatment of all HPV-related cancers[J].Med J Islam Repub Iran,2021,35:65.
• [26]MOREIRA E D,GIULIANO A R,PALEFSKY J,et al.Incidence,clearance,and disease progression of genital human papillomavirus infection in heterosexual men[J].J Infect Dis,2014,210(2):192-199.
• [27]GAO S,MARTCHEVA M,MIAO H,et al.A Dynamic model to assess human papillomavirus vaccination strategies in a heterosexual population combined with men who have sex with men[J].Bull Math Biol,2021,83(1):5.
• [28]ZHU B,LIU Y,ZUO T,et al.The prevalence,trends,and geographical distribution of human papillomavirus infection in China:The pooled analysis of 1.7 million women[J].Cancer Med,2019,8(11):5373-5385.
• [29]PINGALI C,YANKEY D,ELAM-EVANS L D,et al.National,regional,state,and selected local area vaccination coverage among adolescents aged 13-17 years-United States,2020[J].Morb Mortal Wkly Rep,2021,70(35):1183-1190.
• [30]HANNA E,BACHMANN G.HPV vaccination with Gardasil:a breakthrough in women′s health[J].Expert Opin Biol Ther,2006,6(11):1223-1227.
• [31]CROSBIE E J,KITCHENER H C.Cervarix(TM)-a bivalent L1virus-like particle vaccine for prevention of human papillomavirus type 16-and 18-associated cervical cancer[J].Expert Opin Biological Ther,2007,7(3):391-396.
• [32]PRINTZ C.FDA approves Gardasil 9 for more types of HPV[J].Cancer,2015,121(8):1156-1157.
• [33]TANG J,LI M,ZHAO C,et al.Therapeutic DNA vaccines against HPV-related malignancies:Promising leads from clinical trials[J].Viruses,2022,14(2).doi:10.3390/v14020239
• [34]SABADO R L,BALAN S,BHARDWAJ N.Dendritic cellbased immunotherapy[J].Cell Res,2017,27(1):74-95.
• [35]BHUYAN P K,DALLAS M,KRAYNYAK K,et al.Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL[J].Hum Vaccin&Immunother,2021,17(5):1288-1293.
• [36]CABO BELTRAN O R,ROSALES LEDEZMA R.MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis[J].Head Neck,2019,41(3):657-665.
• [37]BOILESEN D R,NIELSEN K N,HOLST P J.Novel antigenic targets of HPV therapeutic vaccines[J].Vaccines,2021,9(11):1262.
• [38]BERGMAN H,BUCKLEY B S,VILLANUEVA G,et al.Comparison of different human papillomavirus(HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males[J].Cochrane Database Syst Rev,2019(11):156.
• [39]MONDATORE D,BAI F,AUGELLO M,et al.Persistence of high percentage of peripheral activated CD8+T cells predict cytologic HPV-related dysplasia in c ART-treated,HIV-positive subjects[J].Open Forum Infect Dis,2022,9(4):ofac046.doi:10.1093/ofid/ofac046.
• [40]ZHANG J Y,CHENG K Y,WANG Z L.Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China:a meta-analysis[J].Arch Gynecol Obstetr,2020,302(6):1329-1337.
• [41]LI Z H,WANG D N,GU Y,et al.Crystal structures of two immune complexes identify determinants for viral infectivity and type-specific neutralization of human papillomavirus[J].Mbio,2017,8(5):e00787-17.doi:ARTN e00787-1710.1128/m Bio.00787-17.
• [42]LI Z H,SONG S,HE M Z,et al.Rational design of a tripletype human papillomavirus vaccine by compromising viral-type specificity[J].Nat Communi,2018,9(11):5360.
• [43]WANG D N,LIU X L,WEI M X,et al.Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles[J].Nat Communi,2020,11(1):2841.
• [44]SCHELLENBACHER C,HUBER B,SKOLL M,et al.Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity[J].Vaccine,2019,37(27):3529-3534.
• [45]YADAV R,ZHAI L K,KUNDA N K,et al.Mixed bacteriophage MS2-L2 VLPs elicit long-lasting protective antibodies against HPV pseudovirus 51[J].Viruses-Basel,2021,13(6).doi:ARTN 111310.3390/v13061113.
• [46]ZHAI L K,YADAV R,KUNDA N K,et al.Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head&neck cancers and cervical cancer[J].Antiviral Res,2019,166:56-65.
• [47]JAGU S,KWAK K,SCHILLER J T,et al.Phylogenetic considerations in designing a broadly protective multimeric L2vaccine[J].J Virol,2013,87(11):6127-6136.
• [48]AYESHA N,ABOULAGHRAS S,JAHANGEER M,et al.Physiopathology and effectiveness of therapeutic vaccines against human papillomavirus[J].Environ Sci Pollution Res,2021,28(35):47752-47772.
• [49]ZHU L,LEI Z,XIA X,et al.Yeast shells encapsulating adjuvant AS04 as an antigen delivery system for a novel vaccine against Toxoplasma gondii[J].ACS Appl Mater Interfaces,2021,13(34):40415-40428.
• [50]LABIANO S,ROH V,GODFROID C,et al.CD40 agonist targeted to fibroblast activation protein alpha synergizes with radiotherapy in murine HPV-positive head and neck tumors[J].Clin Cancer Res,2021,27(14):4054-4065.
• [51]JIANG M,CHEN P,WANG L,et al.c GAS-STING,an important pathway in cancer immunotherapy[J].J Hematol Oncol,2020,13(1):81.
• [52]LUO M,WANG H,WANG Z H,et al.A STING-activating nanovaccine for cancer immunotherapy[J].Nat Nanotechnol,2017,12(7):648.